What is the current state of radiotherapy for the treatment of bladder cancer?
August 2nd 2023“I think radiation therapy in bladder cancer could be divided into organ preservation, which is more for localized bladder cancer, as well as palliative approaches, which is very well known,” says Monika Joshi, MD, MRCP.
Dr. Patel previews BCAN Think Tank discussion on the carcinogenesis of bladder cancer
August 2nd 2023"We've made a lot of big strides in smoking incidence, however, we're still seeing the bladder cancer rates, even though a slight decrease, we're still seeing it holding on," says Sunil H. Patel, MD, MA.
Dr. Spratt on the potential use of an AI biomarker in treatment decision making for prostate cancer
July 28th 2023“The real immediate use case is that this biomarker can be an adjunct, or it can be something to assist in making the shared decision making with patients [with prostate cancer],” says Daniel E. Spratt, MD.
Expert discusses future work on an affordable medications toolkit for urologists
July 24th 2023"We're currently putting together... a toolkit that we can give to urologists and other providers in the community to help counsel their patients on some of the different avenues that they can go down to find more affordable medications," says Brian Cortese.
Dr. Emamekhoo on how his institute is addressing the cancer drug shortage
July 19th 2023“One of the things we do is communicate with our teams and help them with some guidance about how to make decisions about which patients can potentially be treated with alternative approaches,” says Hamid Emamekhoo, MD.
Dr. Burton discusses Aquablation outcomes in men with urinary retention
July 19th 2023"What we found is that those with acute urinary retention took longer to ultimately pass their trial without a catheter, meaning that they were voiding without the use of any catheterization," says Claire S. Burton, MD.
Additional TRAVERSE data on testosterone therapy coming soon
July 18th 2023“Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub studies,” says A. Michael Lincoff, MD.